Description: The HI111 monoclonal antibody reacts with human CD11a, the 180 kDa integrin alphaL, also known as the lymphocyte function associated antigen-1 (LFA-1) alpha chain. LFA-1, formed by non-covalent association of CD11a with CD18 (integrin beta2), serves as an important adhesion molecule involved in lymphocyte and granulocyte function. CD54 (ICAM-1), CD102 (ICAM-2), and CD50 (ICAM-3) are ligands for LFA-1. CD11a is expressed by all leukocytes.
Applications Reported: The HI111 antibody has been reported for use in flow cytometric analysis.
Applications Tested: The HI111 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (1 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser.
Filtration: 0.2 µm post-manufacturing filtered.
CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. Two transcript variants encoding different isoforms of CD11a have been found. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: antigen CD11A (p180); antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide; antigen CD11A p180; CD11 antigen-like family member A; CD11a; integrin alpha L; Integrin alpha-L; integrin alphaL; integrin gene promoter; integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide); Leukocyte adhesion glycoprotein LFA-1 alpha chain; Leukocyte function-associated molecule 1 alpha chain; LFA-1 alpha; LFA-1A; lymphocyte function-associated antigen 1; lymphocyte function-associated antigen 1, alpha polypeptide
Gene Aliases: CD11A; ITGAL; LFA-1; LFA1A
UniProt ID: (Human) P20701
Entrez Gene ID: (Human) 3683